Pravastatin

When ATH:
C10AA03

Characteristic.

White or colorless crystalline powder. It is soluble in water, slightly soluble in isopropanol, and practically insoluble in acetone, acetonitrile and chloroform.

Pharmacological action.
Hypolipidemic.

Application.

Hyperlipidemia without CHD (reduction in the risk of myocardial infarction), atherosclerosis and coronary heart disease, including myocardial infarction (to slow the progression of atherosclerosis and reduce the likelihood of re-infarction), hyperlipidemia Type II (increase in LDL, VLDL, total cholesterol), familial hypercholesterolemia (in patients with a heart transplant to reduce the likelihood of developing coronary angiopathy).

Contraindications.

Hypersensitivity, liver disease and / or a violation of its functions, pregnancy, lactation, children's, adolescence and early adulthood (to 18 years).

Pregnancy and breast-feeding.

Contraindicated in pregnancy.

Category actions result in FDA - X. (Animal tests or clinical trials revealed a violation of the fetus and / or there is evidence of the risk of adverse effects on the human fetus, obtained in research or practice; risk, associated with the use of drugs in pregnancy, greater than the potential benefits.)

At the time of treatment should stop breastfeeding.

Side effects.

Dysfunction of cranial nerves (taste disturbance, involuntary eye movement, paresis of the facial nerve), tremor, dizziness, alarm, insomnia, depression, amnesia, paresthesia, peripheral polyneuropathy, pancreatitis, hepatitis (including chronic active and cholestatic), jïrovaya infiltration, cirrhosis or liver necrosis, gepatoma, anorexia, nausea, myopathy, arthralgia, acute renal failure on a background of rhabdomyolysis, gynecomastia, decreased libido and potency, the progression of cataracts, ophthalmoplegia, alopecia, nodulation and dispigmentation skin, dryness of skin and mucous membranes, respiratory disorders, toxic epidermal necrosis, erythema multiforme, Syndrome Stevens - Johnson, increase plasma concentration of AST and ALT (2-3 times compared with the norm), creatine (CPK), Alkaline phosphatase, bilirubin, photosensitivity, allergic reactions (anaphylactic shock, angioedema, lupus-like syndrome, Rheumatoid polialgiya, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, gemoliticheskaya anemia, eozinofilija, arthritis, hives).

Cooperation.

Increases effect of anticoagulants. Makrolidы, a nicotinic acid, immunosuppressants, Other lipid-lowering drugs increase the risk of rhabdomyolysis with acute renal failure (combined use is not recommended).

Overdose.

There are reports of two cases of overdose is manifested by changes of biochemical blood analysis.

Treatment: symptomatic.

Dosing and Administration.

Inside, 1 once a day, before bedtime. Initial dose is 10-20 mg (patients with pathology of the liver and/or kidney disorder — 10 mg). If no result for 4 weeks dose gradually increased to 40 mg. In most cases, an effective daily dose is 20 mg. For people, receiving immunosuppressive drugs (cyclosporine), mandatory monitoring of CK levels and symptoms of rhabdomyolysis.